Q3 EPS Estimates for Genmab A/S Lowered by Leerink Partnrs

Key Points

• Leerink Partners has lowered its Q3 2025 earnings per share (EPS) estimate for Genmab A/S to $0.41, down from the previous estimate of $0.42.
• Despite the adjustment, Genmab reported a Q2 EPS of $0.54, exceeding analysts' expectations of $0.39.
• Analyst ratings for Genmab remain positive, with multiple upgrades and a consensus target price of $40.80.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Equities researchers at Leerink Partnrs lowered their Q3 2025 EPS estimates for Genmab A/S in a report issued on Sunday, October 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $0.41 per share for the quarter, down from their prior estimate of $0.42. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. Leerink Partnrs also issued estimates for Genmab A/S's Q4 2025 earnings at $0.52 EPS and FY2025 earnings at $1.78 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS.

A number of other research analysts also recently weighed in on the stock. Guggenheim upgraded shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price objective on the stock in a research report on Tuesday, September 23rd. Zacks Research raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. Weiss Ratings reissued a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Truist Financial raised their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Finally, HC Wainwright raised their target price on shares of Genmab A/S from $36.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and a consensus target price of $40.80.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $32.68 on Tuesday. The stock has a market capitalization of $20.98 billion, a P/E ratio of 16.42, a P/E/G ratio of 1.79 and a beta of 0.98. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $33.63. The company's 50-day moving average is $27.07 and its 200 day moving average is $23.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. Orbis Allan Gray Ltd lifted its stake in Genmab A/S by 102.8% during the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock valued at $111,816,000 after acquiring an additional 2,895,179 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company's stock valued at $71,367,000 after acquiring an additional 2,084,966 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company's stock valued at $24,634,000 after acquiring an additional 665,893 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Genmab A/S by 111.5% in the 1st quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company's stock valued at $21,149,000 after purchasing an additional 569,345 shares during the period. Finally, ABC Arbitrage SA acquired a new position in shares of Genmab A/S in the 2nd quarter valued at $9,236,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.